- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01722734
Preserving ACTs - Text Reminders to Increase Adherence to ACT Treatment (PACT)
February 3, 2014 updated by: Günther Fink, Harvard School of Public Health (HSPH)
A randomized controlled trial was conducted to assess the effectiveness of text reminders sent to ACT users through an automated text messaging system short-message-system.
Study hypothesis: text message reminders increase adherence
Study Overview
Detailed Description
A randomized controlled trial was conducted to assess the effectiveness of text reminders sent to ACT users through an automated text messaging system short-message-system.
Patients were enrolled at clinics and pharmacies upon receipt of ACTs and enrolled in the automated system for 3 days.
Study Type
Interventional
Enrollment (Actual)
1140
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Northern Region
-
Tamale, Northern Region, Ghana
- Study Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
-subjects acquiring ACTs in Tamale, Ghana
Exclusion Criteria:
- subjects acquiring ACTs for non household members
- subjects under the age of 18
- subjects without access to cell phones
- subjects living more than 30 minutes from pickup location
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
Patients in the control arm only got a generic health message at the end of the study.
|
|
Active Comparator: Short Message
Patients in this arm receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals.
|
Patients in the two treatment arms receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals to remind them to take their malaria medication as prescribed.
|
Active Comparator: Long message
Patients in this arm receive six long text message reminders (reminders including justification for why patients should finish medication) within 60 hours of treatment initiation at 12 hour intervals.
|
Patients in the two treatment arms receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals to remind them to take their malaria medication as prescribed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Self-reported Adherence to Artemisinin-combination Therapy (ACT) Treatment
Time Frame: 70 hours
|
Percentage of participants completing full ACT treatment regimen 70 hours after treatment initiation.
Subjects were visited at home, and asked to report when each of the prescribed six doses were taken.
Adherence was defined as the (self-reported) completion of all six doses.
|
70 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Gunther Fink, PhD, Harvard School of Public Health (HSPH)
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2011
Primary Completion (Actual)
December 1, 2011
Study Completion (Actual)
January 1, 2013
Study Registration Dates
First Submitted
November 2, 2012
First Submitted That Met QC Criteria
November 5, 2012
First Posted (Estimate)
November 7, 2012
Study Record Updates
Last Update Posted (Estimate)
March 21, 2014
Last Update Submitted That Met QC Criteria
February 3, 2014
Last Verified
February 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19850-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
Clinical Trials on Text message reminders
-
Columbia UniversityPfizerCompletedVaccinationUnited States
-
Children's Hospital of PhiladelphiaCompletedPelvic Inflammatory DiseaseUnited States
-
University of Texas Southwestern Medical CenterUniversity of California, DavisCompleted
-
Wake Forest University Health SciencesCompleted
-
Children's Hospitals and Clinics of MinnesotaUnknownMental Health Disorder | Mental and Behavioral Disorder | Self-inflicted Injury
-
Children's Hospital Medical Center, CincinnatiCMSTextCompleted
-
Wayne State UniversityAgency for Healthcare Research and Quality (AHRQ)CompletedHypertensionUnited States
-
Stanford UniversityCompletedCeliac DiseaseUnited States
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)CompletedHuman PapillomavirusUnited States
-
University of Texas Southwestern Medical CenterRecruitingSuicideUnited States